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Background
CD137 is a potent costimulatory immunoreceptor and a
member of the TNF-receptor (TNFR) superfamily. The
receptor, also known as 4-1BB, is mainly expressed on
activated CD4+ and CD8+ T cells, activated B cells, and
natural killer (NK) cells. While multiple lines of evidence
show that CD137 is a highly promising therapeutic target,
current approaches are not designed to achieve a tumor-
target driven activation. Thus, these approaches may dis-
play a limited therapeutic window due to peripheral T cell
and NK cell activation, leading to unwanted toxicity. To
overcome this limitation, we generated a bispecific protein
therapeutic binding to CD137 and to a differentially
expressed tumor target, HER2.
Methods
Anticalin® proteins are 18 kD protein therapeutics
derived from human lipocalins. We utilized phage display
to generate an Anticalin protein binding to CD137 with
high affinity and specificity. The CD137-specific Antica-
lin protein was genetically fused to a trastuzumab variant
at different positions, yielding four different constructs
covering a range of distances between the binding sites of
the T cell-target and the tumor cell target. To minimize
Fcg-receptor interaction of the resulting bispecific and
concomitant potential toxicity towards CD137-positive
cells, the backbone of trastuzumab was switched from
IgG1 to an engineered IgG4 isotype.
Results
All four bispecific constructs bound the targets CD137
and HER2 with a nearly identical affinity compared to the
parental building blocks, and both targets could be
simultaneously bound. Compared to non-engineered tras-
tuzumab, binding to human receptors FcgRI and FcgRIII
was significantly reduced, while binding to the neonatal Fc
receptor (FcRn) was retained. All constructs were found to
be fully stable in human and mouse plasma, and in mice
displayed pharmacokinetics similar to trastuzumab. HER2-
dependent agonistic engagement of CD137 was demon-
strated in ex-vivo T cell activation assays utilizing HER2-
positive human cell lines. The functional activity of the
bispecific constructs was found to be dependent on their
geometry.
Conclusion
We report the first bispecific therapeutic protein that
targets the potent costimulatory immunoreceptor
CD137 in a tumor-target dependent manner, utilizing
HER2 as the tumor target. Compared to currently exist-
ing CD137-targeting antibodies, this approach has the
potential to provide a more localized activation of the
immune system with reduced peripheral toxicity. Bispe-
cific T cell engagers based on CD137 and HER2 may
have utility in HER2-positive cancers where there is a
significant unmet medical need.
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